ABBV · Earnings call · 2026Q3T · Full report
Payer Access and Reimbursement
AbbVie Inc. · 2026-10-30 · Importance 26 · Surprise 24 · In source text
Management said it was beginning to close arrangements with large PBMs and payers and anticipated very strong access for its portfolio, citing physician demand and product profiles. For immunology, it described low-single-digit rebate concessions as a continuing pattern and expected favorable access for Rinvoq's pending vitiligo and alopecia areata indications. For frontline Epkinly, management expected its single-agent addition to familiar R-CHOP to be straightforward for clinicians and to resonate with HTAs and payers, supporting adoption across markets.
Key facts
- AbbVie expects Skyrizi Crohn's subcutaneous induction to gain full access in approximately 60 days or somewhat longer, with rapid share acceleration in the first part of 2027 into the second quarter.
- AbbVie said its immunology payer-access modeling assumption for 2027 should include a low-single-digit rebate concession.
- AbbVie expects favorable payer access for Rinvoq's pending vitiligo and alopecia areata indications in 2027.
- AbbVie is closing arrangements with large PBMs and payers and expects its portfolio to have very strong access.
- AbbVie said it missed the Medicare access window for tavapadon in 2027.
- AbbVie said possible early additions for tavapadon are speculative, and that current access is unavailable while patients enroll and pursue medical exception processes.
Impact estimates
| metric | direction | stage | expected | basis |
|---|---|---|---|---|
| revenue | positive | probable | — | AbbVie expects Skyrizi Crohn's subcutaneous induction to gain full access in approximately 60 days or somewhat longer, with rapid share… |